UC Davis Health
Welcome,         Profile    Billing    Logout  
 86 Trials 
191 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Creinin, Mitchell D
NCT04457076: Evaluation of the Efficacy, Safety, and Tolerability of LevoCept

Not yet recruiting
3
1525
US
LevoCept
Sebela Women's Health Inc., PRA Health Sciences
Contraception, Women at Risk for Pregnancy
01/29
01/31
NCT04143659: A Study to Evaluate the PK and PD of IM or SQ Injections of Levonorgestrel Butanoate (LB) for Female Contraception

Recruiting
1
136
US
levonorgestrel butanoate (LB) injection
Health Decisions, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Healthy Women, Female Contraception
09/24
09/24
NCT06127199: Contraceptive Efficacy Study of Ovaprene

Recruiting
N/A
656
US
Ovaprene
Daré Bioscience, Inc., Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Contraception
06/25
09/25
McDonald, Craig M
HOPE-3, NCT05126758: A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

Active, not recruiting
3
104
US
Deramiocel (CAP-1002), Cardiosphere-Derived Cells (CDCs), Placebo
Capricor Inc.
Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn, Nervous System Diseases
12/25
12/27
ENVISION, NCT05881408 / 2020-002372-13: A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

Recruiting
3
148
Europe, Japan, US, RoW
delandistrogene moxeparvovec, SRP-9001, delandistrogene moxeparvovec-rokl, ELEVIDYS, placebo
Sarepta Therapeutics, Inc., Hoffmann-La Roche
Duchenne Muscular Dystrophy
05/27
06/28
HOPE-2-OLE, NCT04428476: Open-label Extension of the HOPE-2 Trial

Active, not recruiting
2
13
US
Deramiocel (CAP-1002), Allogeneic Cardiosphere-Derived Cells
Capricor Inc.
Duchenne Muscular Dystrophy
02/22
03/26
MOMENTUM, NCT04004065 / 2019-000601-77: Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Efficacy (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment

Checkmark From MOMENTUM trial for DMD
May 2021 - May 2021: From MOMENTUM trial for DMD
Checkmark Interim data from the MOMENTUM study
Dec 2020 - Dec 2020: Interim data from the MOMENTUM study
Checkmark Data from MOMENTUM trial for Duchenne muscular dystrophy
More
Active, not recruiting
2
62
Europe, Canada, US
Vesleteplirsen, SRP-5051
Sarepta Therapeutics, Inc.
Duchenne Muscular Dystrophy
10/23
01/29
NCT06138639: A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

Recruiting
1/2
43
Canada, US
SGT-003
Solid Biosciences Inc.
Duchenne Muscular Dystrophy
05/27
05/31
NCT03863119: Expanded Access Protocol for Boys With Duchenne Muscular Dystrophy

Available
N/A
Canada, US, RoW
Vamorolone
Santhera Pharmaceuticals
Duchenne Muscular Dystrophy
 
 
NCT04475926: A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice

Recruiting
N/A
241
Europe, Canada, US, RoW
Sarepta Therapeutics, Inc.
Limb-girdle Muscular Dystrophy
04/30
04/30
Kiaii, Bob
TRIOMPHE, NCT04471909: NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness

Recruiting
N/A
110
US, RoW
NEXUS Aortic Stent Graft System
Endospan Ltd.
Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer
11/24
10/29
NCT04198870: MitraClip REPAIR MR Study

Recruiting
N/A
500
Europe, Canada, US
MitraClip™ device implantation, Mitral Valve Repair Surgery
Abbott Medical Devices
Mitral Valve Regurgitation
04/26
04/34
Bowlus, Christopher L
NCT04950127 / 2021-000007-21: Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Linerixibat, Placebo
GlaxoSmithKline
Pruritus
10/24
01/25
LLSAT, NCT04167358 / 2019-003158-10: Linerixibat Long-term Safety, and Tolerability Study

Recruiting
3
251
Europe, Canada, Japan, US, RoW
Linerixibat
GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited
Cholestasis
02/27
02/27
SHIP, NCT03561584: Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis

Recruiting
2
42
US
Sulfasalazine, Azulfidine, Placebo
Brigham and Women's Hospital
Primary Sclerosing Cholangitis
09/24
11/24
NCT05239468 / 2022-001241-20: Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Active, not recruiting
2
60
US
Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo
Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc.
Primary Biliary Cholangitis
11/24
02/25
SPRING, NCT04595825 / 2019-002945-39: CM-101 in PSC Patients -The Study

Active, not recruiting
2
68
Europe, US, RoW
Anti-human CCL24 monoclonal antibody (CM-101), Placebo
ChemomAb Ltd., ChemomAb Ltd
Primary Sclerosing Cholangitis
09/24
09/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT06699121: A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

Not yet recruiting
2
87
US
LB-P8 low-dose, LB-P8 high-dose, Placebo
LISCure Biosciences
Primary Sclerosing Cholangitis (PSC)
03/28
02/29
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects

Recruiting
2
240
US, RoW
HM15211, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
05/26
11/26
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting
2
271
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
12/25
03/26
NCT05104853: Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis

Active, not recruiting
1/2
42
US
CNP-104, Placebo
COUR Pharmaceutical Development Company, Inc.
Primary Biliary Cholangitis
01/26
01/26
Herman, Daniel
NCT04472702: Fluoroscopic Versus Ultrasound Guidance for Cooled Radiofrequency Ablation of Geniculate Nerves in Knee Osteoarthritis: A Randomized Control Trial

Recruiting
N/A
90
US
cRFA
University of California, Davis, American Medical Society for Sports Medicine Collaborative Research Network
Knee Osteoarthritis
10/25
10/25
Fleming, Neal W
NCT05478174: Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia

Completed
3
400
US
HSK3486, Propofol, Diprivan
Haisco-USA Pharmaceuticals, Inc.
General Anesthesia
11/23
11/23
NCT03075150: PVI as a Parameter to Predict Fluid Responsiveness

Recruiting
N/A
100
US
Masimo Rainbow sensor
University of California, Davis, Masimo Corporation
Surgery
07/19
07/19
NCT04730063: Evaluation of Novel Cardio-Pulmonary Physiological Monitor, the VQm PHM™, for Acute Care Medicine

Recruiting
N/A
40
US
VQm PHM™
Rostrum Medical Innovations Inc., University of California, Davis
Elective Procedures Requiring Mechanical Ventilation
01/23
02/23
NCT05025176: Hypotension Prediction Index: Correlations Between Invasive and Non-invasive Pressure Points.

Active, not recruiting
N/A
50
US
Non invasive arterial pressure monitoring
University of California, Davis
Hypotension
08/25
08/25
NCT05859672: Ventilation and Esophageal Pressure Changes

Recruiting
N/A
150
US
University of California, Davis
Mechanical Ventilation
01/25
01/25
NCT04726852: Arterial Pressure vs. TE Echo dp/dt

Active, not recruiting
N/A
43
US
Concurrent comparison
University of California, Davis
Myocardial Contraction
01/25
07/25
NCT05886218: Quantitative Neuromuscular Monitoring and Gastric Bypass Surgery

Recruiting
N/A
215
US
Quantitative Neuromuscular Function Monitoring
University of California, Davis
Sugammadex
02/25
07/25
NCT01997502: Accuracy of Pulse CO-Oximetry Technology in Characterizing Noninvasive SpHb

Recruiting
N/A
300
US
Pulse CO-Oximetry Technology, Blood draw
University of California, Davis
Surgery, Hemoglobin
01/25
01/25
NCT01815983: Video-Assisted Laryngoscopy Education

Withdrawn
N/A
40
US
Videolaryngoscopy review.
University of California, Davis
Surgery
06/24
06/24
Abedi, Mehrdad
E-CELERATE, NCT05181540: A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

Terminated
3
130
US
AB-205, E-CEL cells, Placebo
Angiocrine Bioscience, California Institute for Regenerative Medicine (CIRM)
Hodgkin Lymphoma, Non Hodgkin Lymphoma
12/23
01/25
GRASP, NCT05353647: A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (, BMT CTN 2001)

Active, not recruiting
2
25
US
Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
David Williams, National Heart, Lung, and Blood Institute (NHLBI), California Institute for Regenerative Medicine (CIRM), bluebird bio, Blood and Marrow Transplant Clinical Trials Network
Sickle Cell Disease
05/26
05/26
EBVision, NCT04554914 / 2020-000177-25: A Study to Evaluate Tabelecleucel in Participants with Epstein-barr Virus-associated Diseases

Hourglass Jan 2023 - Dec 2023 : From P2 trial for Epstein-Barr virus-associated sarcoma
Recruiting
2
190
Europe, US
Tabelecleucel, tab-cel®, ATA129, EBV-CTLs
Atara Biotherapeutics
Epstein-Barr Virus (EBV)-associated Diseases, EBV+ Lymphoproliferative Disease with Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease with Acquired (non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma
06/27
05/29
NCT02797470: Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

Active, not recruiting
1/2
11
US
Autologous Hematopoietic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Carmustine, BCNU, Becenum, Becenun, BiCNU, Bis(chloroethyl) Nitrosourea, Bis-Chloronitrosourea, Carmubris, Carmustin, Carmustinum, FDA 0345, Gliadel, N,N'-Bis(2-chloroethyl)-N-nitrosourea, Nitrourean, Nitrumon, SK 27702, SRI 1720, WR-139021, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, Laboratory Biomarker Analysis, Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells, Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive HPCs, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplantation
AIDS Malignancy Consortium, National Cancer Institute (NCI), California Institute for Regenerative Medicine (CIRM)
HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Follicular Lymphoma, Stage III Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Follicular Lymphoma, Stage IV Mantle Cell Lymphoma
05/21
06/25
Starlight-1, NCT06343311: T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Recruiting
1/2
21
US
EB103
Estrella Biopharma, Inc., Eureka Therapeutics Inc.
B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell, Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Large B-Cell Lymphoma, Lymphoma, Non-Hodgkin's, Adult, Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Lymphoma, Non-Hodgkin, HIV Associated Lymphoma, CNS Lymphoma, High-grade B-cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
12/26
12/27
FELIX, NCT04404660: A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Hourglass Jul 2024 - Dec 2024 : Submission in UK for adult r/r B-ALL
Active, not recruiting
1/2
153
NA
AUTO1, Obecabtagene autoleucel (obe-cel)
Autolus Limited
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
05/25
05/25
NCT04648046: CAR-T Cells for HIV Infection

Recruiting
1/2
18
US
Cyclophosphamide, LVgp120duoCAR-T cells, low dose, LVgp120duoCAR-T cells, high dose, Analytic Treatment Interruption
Steven Deeks, Caring Cross
HIV Infections
12/27
12/28
LIMBER-TREG108, NCT05423691: Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

Recruiting
1
24
US
CK0804
Cellenkos, Inc.
Myelofibrosis
04/24
04/24
BMSCRP1, NCT04925687: Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa

Completed
1
4
US
Intravitreal autologous CD34+ cells
University of California, Davis, Cures Within Reach, The Retina Society
Retinitis Pigmentosa
11/23
11/23
OGFT001-001, NCT03802695: A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Recruiting
1
186
US
OrcaGraft (Orca-Q)
Orca Biosystems, Inc.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Myelofibrosis, Chronic Myeloid Leukemia
04/26
04/28
NCT05052528: Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recruiting
1
36
US
Chimeric Antigen Receptor T-Cell Therapy, CAR T Infusion, CAR T Therapy, CAR T-cell Therapy, Chimeric Antigen Receptor T-cell Infusion, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
Mehrdad Abedi, MD, National Cancer Institute (NCI)
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
05/25
12/25
NEXICART-2, NCT06097832: Study of NXC-201 CAR-T in Patients with Light Chain (AL) Amyloidosis

Recruiting
1
40
US
NXC-201 CAR-T, HBI0101 CAR-T
Nexcella Inc., Immix Biopharma, Inc.
Light Chain (AL) Amyloidosis
12/26
01/39
NCT04422912: A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Recruiting
1
55
US
DSG3-CAART or CABA-201
Cabaletta Bio
Pemphigus Vulgaris
01/29
01/29
Waetjen, Elaine
NCT04758247: Evaluation of the TheraNova Neuromodulation System for the Treatment of Overactive Bladder Symptoms

Completed
N/A
12
US
TheraNova Neuromodulation System
Theranova, L.L.C.
Overactive Bladder
12/23
12/23
NCT05162833: Evaluation of the TheraNova Neuromodulation System to Provide Durable Relief of Overactive Bladder Symptoms

Completed
N/A
3
US
TheraNova Neuromodulation Device
Theranova, L.L.C.
Overactive Bladder
12/23
12/23
Ali, Mohamed R
NCT05652998: Comparison Between Intralesional Injection of Plasma Rich Platelets and Candida Antigen in Plane Warts

Active, not recruiting
4
30
RoW
C. albicans antigen, autologous PRP, saline
Qena Faculty of medicine, South Valley University
Plane Wart
12/22
04/23
NCT04240626: Multimodal Analgesia Effect on Post Surgical Patient

Recruiting
4
60
US
Neurontin, Gabapentin, Dilaudid Injectable Product, Hydromorphone, Marcaine Injectable Product, Oxycodone Hydrochloride, Hycet 7.5Mg-325Mg/15Ml Solution, Hydrocodone, Zofran Injection, Odanesetron, Scopolamine patch, Scopolamine, Ativan, Flexeril Oral Product, Cyclobenziparin, Tylenol Suspension, Acetaminophen
University of California, Davis
Obesity, Morbid, Surgery, Bariatric Surgery Candidate
12/24
12/25
NCT05156047: A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia

Completed
3
214
US
Open-label pitolisant, Double-blind placebo, Double-blind pitolisant
Harmony Biosciences, LLC
Idiopathic Hypersomnia
09/23
09/23
FORCE2, NCT05292586: A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared to CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid

Completed
3
610
US
Beclomethasone Dipropionate/Formoterol Fumarate, BDP/FF, Beclomethasone Dipropionate, BDP
Chiesi Farmaceutici S.p.A.
Asthma
06/24
06/24
ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Recruiting
3
234
US
Clofazimine Inhalation Suspension, MNKD-101, Placebo
Mannkind Corporation
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
08/26
12/28
NCT05668754: Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH

Completed
2
50
US
Serdexmethylphenidate, SDX, Placebo
Zevra Therapeutics, Rho, Inc.
Idiopathic Hypersomnia
02/24
03/24
PTK0796-NTM-20203, NCT04922554: Oral Omadacycline Vs. Placebo in Adults with NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

Completed
2
66
US
Omadacycline Oral Tablet, Nuzyra, Placebo, placebo tablets
Paratek Pharmaceuticals Inc
Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterial Pulmonary Infection
06/24
07/24
NCT05093920: Role of DEB-TACE Versus c-TACE in Treatment of HCC

Active, not recruiting
1
30
RoW
Doxorubicin-Eluting Beads, Lipidol-Doxorubicin emulsion
Sohag University
Hepatocellular Carcinoma
12/23
01/24
NCT04556409: US vs. LASER on Post Cesarean Anterior Cutaneous Branches of Iliohypogastric Neurotmesis

Not yet recruiting
N/A
45
RoW
low intensity pulsed ultrasound plus static abdominal and pelvic floor exercises., low level LASER plus static abdominal and pelvic floor exercises., static abdominal and pelvic floor exercises only.
South Valley University
Neurotmesis
11/21
12/21
NCT06600945: Atracurium Versus Atracurium and Magnesium Sulphate As Adjuvants to Local Anesthetic

Recruiting
N/A
180
RoW
Cataract surgery
Dalia yousry Mohamed elsayed, Minia University
Peribulbar Anesthesia
04/24
04/25
NCT05624957: Lidocaine Irrigation in Shoulder Arthroscopy

Completed
N/A
50
RoW
Lidocaine epinephrine, Epinephrin
Minia University
Postoperative Pain, Analgesia
05/23
08/23
NCT05281796: Evaluation of Galectin-3 Levels in GCF And Saliva of Patients With Different Periodontal Diseases

Completed
N/A
66
RoW
GCF obtaining, saliva obtaining
Cairo University
Periodontal Diseases
06/23
08/23
NCT06222814: Evaluation of the Results of Two Different Methods in Management of Antero-lateral Instability of the Knee

Recruiting
N/A
40
RoW
ACL reconstruction combined with anterolateral ligament reconstruction using peroneus longus autograft, ACL reconstruction combined with extra-articular tenodesis (Modified Lemaire)
Sohag University
Anterior Cruciate Ligament Injuries
08/25
08/25
NCT06031571: Effect of Dynamic Cupping Versus Myofascial Release Therapy in Patients With Mechanical Neck Pain

Recruiting
N/A
38
RoW
dry cupping massage, traditional exercises (neck stretching and strengthening exercises), Myofacial release
South Valley University
Mechanical Neck Pain
07/24
07/24
NCT06148805: Effect of Pilates Exercises and Diaphragm Manual Therapy Techniques in Rotator Cuff Tendinopathy

Recruiting
N/A
60
RoW
pilates exercise and diaphragm manual technique, exercises
Ministry of Health and Population, Egypt, Cairo University
Shoulder Tendinitis, Shoulder Rotator Cuff Tendinopathy
05/24
12/24
NCT06248047: Vessel-sparing Technique Versus Conventional Repair of PFUI: A Prospective Comparative Study

Not yet recruiting
N/A
32
RoW
uretheroplasty
Assiut University
Traumatic Urethral Stricture, Male, Overlapping Sites
01/26
01/26
NCT06566352: Different Methods to Minimize Blood Loss During Laparoscopic Myomectomy; A Randomized Controlled Clinical Trial

Recruiting
N/A
60
RoW
Laparoscopic myomectomy with intramyometrial injection of diluted epinephrine, traditional laparoscopic myomectomy, laparoscopic myomectomy with temporary bilateral uterine artery occlusion, injection of epinephrine 1mg diluted in 200mg of NaCl
Zagazig University
Different Methods to Minimize Blood Loss During Laparoscopic Myomectomy
05/25
05/25
NCT06558578: Association of Helicobacter Pylori Infection and Migraine

Recruiting
N/A
50
RoW
Helicobacter pylori antigen in stool, Upper gastrointestinal tract endoscopy
Sohag University
Migraine in Children
07/25
08/25
NCT06762197: Radial Shockwave Versus Low Level Laser Therapy in Patients With Chronic Piriformis Muscle Syndrome

Not yet recruiting
N/A
63
RoW
Conventional treatment, shockwave therapy, low level laser therapy
Cairo University
Extracorporeal Shock Wave, Radial Shock Wave, Low Level Laser, Piriformis Muscle Syndrome
03/25
04/25
NCT03123835: Outcome Analysis of POEM and Endoluminal Therapies

Enrolling by invitation
N/A
500
US
Endoscopic Intervention, Endoluminal Therapies, POEM, Endoscopic Revision
University of California, Davis
Achalasia, Gastric Fistula, Weight Gain After Primary Weight Loss Surgery, Marginal Ulcer, Stenoses, Gastric Nec
12/30
12/31
NCT02024542: Metabolic Responses to Bariatric Surgery

Recruiting
N/A
500
US
Surgery
University of California, Davis
Morbid Obesity
04/35
04/35
NCT04791930: Evaluation of Vestibular Function in Patients With C.S.O.M: Safe Type

Recruiting
N/A
50
RoW
Assiut University
Vertigo Labyrinthine
04/23
10/23
NCT05645848: The Rate and Predictors of Vaginal Bleeding Among Women With Placenta Previa

Not yet recruiting
N/A
250
NA
Ultrasonography
Assiut University
Placenta Previa, Vaginal Bleeding, Antepartum Hemorrhage
12/24
01/25
NCT05693311: Inflammatory Bowel Disease Related Joint Manifestations

Not yet recruiting
N/A
217
NA
Youstina Yosry Soliman
IBD, Joint Diseases
12/24
03/25
Smith, William B
CHALLENGE-MIG, NCT05127486: A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine

Checkmark Enrollment initiated in combination with Emgality for episodic migraine
Nov 2021 - Nov 2021: Enrollment initiated in combination with Emgality for episodic migraine
Completed
4
580
US
Galcanezumab, LY2951742, Rimegepant, Placebo
Eli Lilly and Company
Migraine, Episodic Migraine
05/23
05/23
NCT05518123 / 2022-001176-34: Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications

Recruiting
4
600
Europe, Canada, US, RoW
Rimegepant, Placebo
Pfizer, Pfizer
Migraine
02/25
08/25
NCT04240626: Multimodal Analgesia Effect on Post Surgical Patient

Recruiting
4
60
US
Neurontin, Gabapentin, Dilaudid Injectable Product, Hydromorphone, Marcaine Injectable Product, Oxycodone Hydrochloride, Hycet 7.5Mg-325Mg/15Ml Solution, Hydrocodone, Zofran Injection, Odanesetron, Scopolamine patch, Scopolamine, Ativan, Flexeril Oral Product, Cyclobenziparin, Tylenol Suspension, Acetaminophen
University of California, Davis
Obesity, Morbid, Surgery, Bariatric Surgery Candidate
12/24
12/25
NCT05590403 / 2022-001981-36: A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above

Completed
3
1544
Europe, Canada, Japan, US, RoW
RSVPreF3 OA investigational vaccine, Placebo
GlaxoSmithKline
Respiratory Syncytial Virus Infections
03/23
04/24
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Active, not recruiting
3
1083
Europe, Canada, US, RoW
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
12/24
02/25
NCT06015282: The Celljuvant Study: a Phase 3 Immunogenicity and Safety Study of AQIVc Vaccine in Adults Aged 50 Years and Older

Active, not recruiting
3
7741
Europe, Canada, US, RoW
Investigational aQIVc, licensed QIV1, licensed QIV2
Seqirus
Influenza, Human
03/24
01/25
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
NCT06389487: A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above

Active, not recruiting
3
1457
Europe, Canada, Japan, US, RoW
RSVPreF3 OA investigational vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
07/24
04/25
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
ORCA-OL, NCT06435221: Safety Study of Cytisinicline in Adult Combustible And/or E-cigarette Smokers

Active, not recruiting
3
650
US
Cytisinicline, Cytisine
Achieve Life Sciences
Smoking Cessation, Vaping Cessation
12/25
12/25
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Active, not recruiting
3
1500
Europe, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Type 2 Diabetes
08/25
08/25
NCT05968430: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hypertension

Enrolling by invitation
3
1400
Europe, Canada, US, RoW
lorundrostat, Placebo
Mineralys Therapeutics Inc.
Hypertension
12/25
12/26
GUIDANCE, NCT05050084: Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score

Recruiting
3
2050
Canada, US
Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Buserelin, 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766, ICI 123215, S74-6766, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, Degarelix, FE200486, Firmagon, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Relugolix, N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, TAK 385, TAK-385, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline
NRG Oncology, National Cancer Institute (NCI)
Prostate Adenocarcinoma
04/32
04/37
PREDICT-RT, NCT04513717: Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The Trial

Recruiting
3
2478
Canada, US
Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Buserelin, 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766, ICI 123215, S74-6766, Degarelix, FE200486, Firmagon, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline
NRG Oncology, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
12/33
12/33
NCT05975060: A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.

Completed
2/3
660
US
XBB.1.5 Vaccine (Booster), Omicron sub variant XBB.1.5 vaccine( booster) SARS-CoV-2 rS /Matrix-M Adjuvant, XBB.1.5 Vaccine (single dose), Omicron sub variant XBB.1.5 vaccine(single dose) SARS-CoV-2 rS /Matrix-M Adjuvant
Novavax
COVID-19
11/23
05/24
NCT04809376: Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain

Active, not recruiting
2/3
602
US, RoW
Pentosan Polysulfate Sodium twice weekly, PPS twice weekly, Placebo (Sodium Chloride Injection, 0.9%), Placebo, Pentosan Polysulfate Sodium Fixed Dose, Fixed Dose, Pentosan Polysulfate Sodium once weekly, PPS once weekly
Paradigm Biopharmaceuticals USA (INC)
Osteoarthritis, Knee
10/24
01/25
NCT05067933: A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine

Completed
2
66
US
VXA-CoV2-1.1-S, Oral Tableted Ad5 COVID-19 Vaccine, Placebo Tablets
Vaxart
COVID-19
05/22
08/23
NCT06431607: A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults

Active, not recruiting
2
838
US
Flu Seasonal mRNA Formulation 1, GSK4382276A, Flu Seasonal mRNA Formulation 2, Flu Seasonal mRNA Formulation 3, Flu Seasonal mRNA Formulation 4, Flu Seasonal mRNA Formulation 5, Flu Seasonal mRNA Formulation 6, Flu Seasonal mRNA Formulation 7, Flu Seasonal mRNA Formulation 8, Active Comparator 1, Active Comparator 2, Flu Seasonal mRNA Formulation 9, Flu Seasonal mRNA Formulation 10, Active Comparator 3, Active Comparator 4
GlaxoSmithKline
Influenza, Human
11/24
06/25
ZUPREME-1, NCT06662539: Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities

Recruiting
2
480
Europe, US
Petrelintide, ZP8396, Placebo
Zealand Pharma, Parexel
Obesity
11/25
04/26
NCT06151288: Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults

Completed
1/2
1015
US
31 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine, PCV20, Prevnar 20™
Vaxcyte, Inc.
Pneumococcal Vaccines
07/24
07/24
NCT05975840: Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults

Completed
1/2
518
US
FLU Q-PAN H5N8 Formulation 1, AS03B, AS03A, FLU Q-PAN H5N8 Formulation 2
GlaxoSmithKline
Influenza, Human
12/23
05/24
NCT05823974: A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

Active, not recruiting
1/2
1256
Europe, Canada, US, RoW
Flu mRNA, GSK4382276A, Control 1, Control 2
GlaxoSmithKline, CureVac
Influenza, Human
07/24
08/24
NCT06680375: A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults

Active, not recruiting
1/2
780
US
Flu Seasonal /SARS-CoV-2 mRNA Dose 1, Flu Seasonal /SARS-CoV-2 mRNA Dose 2, Flu Seasonal mRNA, SARS-CoV-2 mRNA Dose 1, SARS-CoV-2 mRNA Dose 2, Licensed Flu Seasonal, Licensed COVID-19 mRNA, Placebo, Phase 2 selected Investigational Flu Seasonal/SARS-CoV-2 mRNA, Phase 2 selected SARS-CoV-2 mRNA
GlaxoSmithKline
COVID-19
05/25
11/25
NCT05961397: Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic Impairment

Completed
1
20
US
baxdrostat, CIN-107
AstraZeneca
Hypertension
04/22
04/22
Study 1100, NCT03589339: NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy

Recruiting
1
145
US
NBTXR3, SABR, Stereotaxic Ablative Radiotherapy, Stereotaxic Body Radiation Therapy, Nivolumab, Opdivo, Pembrolizumab, Keytruda
Nanobiotix
Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis from Malignant Tumor of Liver, Squamous Cell Carcinoma of Head and Neck, Metastasis from Malignant Tumor of Cervix, Metastatic Renal Cell Carcinoma, Metastasis from Malignant Melanoma of Skin (disorder), Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC, Metastasis from Malignant Tumor of Bladder (Disorder)
04/27
05/28
NCT03896750: Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function

Recruiting
1
36
US
PA-824
National Institute of Allergy and Infectious Diseases (NIAID)
Renal Impairment, Tuberculosis
01/25
07/25
NCT05711381: Phase 1 PK Study to Assess Safety, PK, Tolerability of HM15912 in Subjects With Renal Impairment and Normal Renal Function

Completed
1
16
US
HM15912
Hanmi Pharmaceutical Company Limited
Renal Impairment
08/23
08/23
NCT05194358: Study of SIAN Nasal Spray in Healthy Adults

Completed
1
47
US
Stabilized Isoamyl Nitrite (SIAN)
Emergent BioSolutions, Biomedical Advanced Research and Development Authority
Cyanide Poisoning
09/23
10/23
 

Download Options